📚 Extracted Documents

This document is an order from the Government of India, Ministry of Chemicals & Fertilizers, Department of Pharmaceuticals, regarding a review application filed by La Renon Healthcare Pvt Ltd. The review challenges a price fixation order by the National Pharmaceutical Pricing Authority (NPPA) on the grounds that the NPPA erred in including a modified release formulation in its ceiling price calculations. The document outlines the company's contentions and NPPA's response regarding this pharmaceutical pricing issue.

This document is an order issued by the Ministry of Chemicals and Fertilizers, Government of India, concerning a review application filed by Macleods Pharmaceuticals Limited. The application challenges the price fixation order by the National Pharmaceutical Pricing Authority (NPPA) for certain Metformin and Metoprolol formulations, arguing that these modified release drugs should be priced separately from conventional formulations. The document details the grounds of contention and the interpretation of relevant provisions in the Drugs (Prices Control) Order, 2013.

This document is an order from the Government of India, Department of Pharmaceuticals regarding a review application filed by Abbott Healthcare Private Limited. The application challenges the price fixation order by the National Pharmaceutical Pricing Authority (NPPA) for Metformin tablets. Abbott argues that their modified release formulations should not be included in the price calculation for conventional Metformin 500mg tablets.

This document is an order from the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Government of India. It addresses a review application filed by Abbott Healthcare against a pricing order issued by the National Pharmaceutical Pricing Authority. The document discusses the ceiling price determination for Nitrofurantoin 100mg tablets and argues Abbott's case for excluding their modified release formulations from this ceiling price calculation.

This document is a circular issued by the Indian Ministry of Chemicals and Fertilizers' Department of Pharmaceuticals, addressing amendments to the Uniform Code for Pharmaceutical Marketing Practices 2024. It outlines changes in reporting requirements for marketing expenditures and specifies procedures for valuing free samples. This circular aims to simplify administrative burdens and enhance compliance among pharmaceutical companies.

This document is an official circular issued by the Government of India's Ministry of Chemicals and Fertilizers, Department of Pharmaceuticals. It extends the deadline for the submission of self-declaration and disclosure of marketing expenditure under the Uniform Code for Pharmaceutical Marketing Practices for the financial year 2024-25. Organizations are requested to notify their members about this extension.

This is a circular issued by the Government of India's Ministry of Chemicals and Fertilizers, Department of Pharmaceuticals, regarding a self-declaration requirement under the Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024 for the financial year 2024-25. The circular urges all pharmaceutical associations to circulate the requirement among their members for compliance, with declarations due by June 30, 2024. The document ensures that companies adhere to UCPMP guidelines for ethical pharmaceutical marketing practices.

The document is an official order issued by the Government of India's Department of Pharmaceuticals, detailing the Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024. It instructs pharmaceutical associations to implement this code and establish ethics committees and dedicated portals. This document emphasizes strict adherence to ethical marketing practices for pharmaceuticals.